Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study

Abstract Background Pyrotinib, a novel irreversible epidermal growth factor receptor 2 (EGFR)/HER2 dual tyrosine kinase inhibitor, has shown promising antitumor efficacy with tolerable toxicity in HER2‐positive metastatic breast cancer (MBC) in several clinical trials. However, the clinical trials d...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sha Yin, Yajing Chi, Yangyang Du, Jingfen Wang, Changping Shan, Weiwei Yi, Mao Shang, Xiaochu Man, Qiaorui Tan, Huihui Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2023-02-01
coleção:	Cancer Medicine
Assuntos:	efficacy HER2‐positive breast cancer pyrotinib real‐world study safety
Acesso em linha:	https://doi.org/10.1002/cam4.5056
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!